argenx

Netherlandsargen-x.com
pre-ipo
pre-ipo
Stage
2
Investors

About

argenx SE is a biopharmaceutical company based in the Netherlands that develops differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody.

Explore argenx's full profile on Brouky

Funding rounds, investor list, and risk signals — unlock with a subscription.